Strong T cell type-1 immune responses to HIV-1 Tat (1-72) protein-coated nanoparticles

Vaccine

Volumn 22, Issue 20, 2004, Pages 2631-2640

  Cui, Zhengrong ^a   Patel, Jigna ^a   Tuzova, Marina ^b   Ray, Phillip ^b   Phillips, Ryan ^b   Woodward, Jerold G ^b   Nath, Avindra ^c   Mumper, Russell J ^a  

^a University of Kentucky   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Cytokines; Rodent; Spleen and lymph nodes; Th1 Th2 cells; Vaccination

Indexed keywords

ALUMINUM POTASSIUM SULFATE; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; PROTEIN TAT[1-72]; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS PROTEIN;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG COATING; DRUG EFFECT; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TH2 CELL;

AIDS VACCINES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE; MICE, INBRED BALB C; NANOTECHNOLOGY; PARTICLE SIZE; T-LYMPHOCYTES;

EID: 2942620224     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2003.12.013     Document Type: Article

References (45)

1. Garber M.E., Jones KA. HIV-1 Tat: coping with negative elongation factors. Curr. Opin. Immunol. 11:1999;460-465
2. Bayer P., Kraft M., Ejchart A., Westendorp M., Frank R., Rosch P. Structural studies of HIV-1 Tat protein. J. Mol. Biol. 247:1995;529-535
3. Jones K.A., Peterlin B.M. Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem. 63:1994;717-743
4. Chang H.C., Samaniego F., Nair B.C., Buonaguro L., Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparin sulfate proteoglycans through its basic region. Aids. 11:1997;1421-1431
5. Barillari G.R., Gendelman R., Gallo R.C., Ensoli B. The Tat protein of human immunodeficiency virus type 1, a growth factor for AIDS Kaposi sarcoma and cytokine-activated vascular cells, induces adhesion of the same cell types by using integrin receptors recognizing the RGD amino acid sequence. Proc. Natl. Acad. Sci. U.S.A. 90:1993;7941-7945
6. Ma M., Nath A. Molecular determinants for cellular uptake of Tat protein of human immunodeficiency virus type 1 in brain cells. J. Virol. 71:1997;2495-2499
7. Frankel A.D., Pabo C.O. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell. 55:1988;1189-1193
8. Li C.J., Ueda Y., Shi B., Borodyansky L., Huang L., Li Y.Z., et al. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. Proc. Natl. Acad. Sci. U.S.A. 94:1997;8116-8120
9. Viscidi R.P., Mayur K., Lederman H.M., Frankel A.D. Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1. Science. 246:1989;1606-1608
10. Li C.J., Friedman D.J., Wang C., Metelev V., Pardee A.B. Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein. Science. 268:1995;429-431
11. Kolesnitchenko V., King L., Riva A., Tani Y., Korsmeyer S.J., Cohen D.I. A major human immunodeficiency virus type 1-initiated killing pathway distinct from apoptosis. J. Virol. 71:1997;9753-9763
12. 2+ responses to HIV-1 gp120 in cultured human fetal brain cells. Neuroscience. 91:1999;1369-1378
13. Nath A., Haughey N., Jones M., Anderson C., Bell J., Geiger J. Synergistic neurotoxicity by human immunodeficiency virus proteins Tat and gp120: protection by memantine. Ann. Neurol. 47:2000;186-194
14. Haughey N.J., Holden C.P., Nath A., Geiger J.D. Involvement of inositol 1, 4, 5-trisphosphate-regulated stores of intracellular calcium in calcium dysregulation and neuron cell death caused by HIV-1 protein tat. J. Neurochem. 73:1999;1363-1374
15. Moy P., Daikh Y., Pepinsky B., Thomas D., Fawell S., Barsoum J. Tat-mediated protein delivery can facilitate MHC class I presentation of antigens. Mol. Biotechnol. 6:1996;105-113
16. Fawell S., Seery J., Daikh Y., Moore C., Chen L.L., Pepinsky B., et al. Tat-mediated delivery of heterologous proteins into cells. Proc. Natl. Acad. Sci. U.S.A. 91:1994;664-668
17. Kim D.T., Mitchell D.J., Brockstedt D.G., Fong L., Nolan G.P., Fathman C.G., et al. Introduction of soluble proteins into the MHC class I pathway by conjugation to an HIV Tat peptide. J. Immunol. 159:1997;1666-1668
18. Rossi C., Balboni P.G., Betti M., Marconi P.C., Bozzini R., Grossi M.P., et al. Inhibition of HIV-1 replication by a Tat transdominant negative mutant in human peripheral blood lymphocytes from healthy donors and HIV-1-infected patients. Gene Ther. 4:1997;1261-1269
19. Caputo A., Grossi M.P., Bozzini R., Rossi C., Betti M., Marconi P.C., et al. Inhibition of HIV-1 replication and reactivation from latency by Tat transdominant negative mutants in the cysteine rich region. Gene. Ther. 3:1996;235-245
20. Wu M.X., Schlossman S.F. Decreased ability of HIV-1 Tat protein-treated accessory cells to organize cellular clusters is associated with partial activation of T cells. Proc. Natl. Acad. Sci. U.S.A. 94:1997;13832-13837
21. Dockrell D.H., Badley A.D., Villacian J.S., Heppelmann C.J., Algeciras A., Ziesmer S., et al. The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. J. Clin. Invest. 101:1998;2394-2405
22. Zauli G., Gibellini D., Milani D., Mazzoni M., Borgatti P., La Placa M., et al. Human immunodeficiency virus type 1 Tat protein protects lymphoid, epithelial, and neuronal cell lines from death by apoptosis. Cancer Res. 53:1993;4481-4485
23. Cohen S.S., Li C., Ding L., Cao Y., Pardee A.B., Shevach E.M., et al. Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc. Natl. Acad. Sci. U.S.A. 96:1999;10842-10847
24. Korber B, Hahn B, Foley B, Mellors JW, Leitnes T, Myers G, et al. Human retroviruses and AIDS 1997: a compilation and analysis of nucleic acid and amino acid sequences. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 1997.
25. van Baalen C.A., Pontesilli O., Huisman R.C., Geretti A.M., Klein M.R., de Wolf F., et al. Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol. 78:1997;1913-1918
26. Venet A., Bourgault I., Aubertin A.M., Kieny M.P., Levy J.P. Cytotoxic T-lymphocyte response against multiple simian immunodeficiency virus A (SIV) proteins in SIV-infected macaques. J. Immunol. 148:1992;2899-2908
27. Froebel K.S., Aldhous M.C., Mok J.Y., Hayley J., Arnott M., Peutherer J.F. Cytotoxic T lymphocyte activity in children infected with HIV. AIDS Res. Hum. Retroviruses. 10:1994;S83-S88
28. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1-specific cytotoxic T-lymphocytes and plasma load of viral RNA. Science. 279:1998;2103-2106
29. Re M.C., Furlini G., Vignoli M., Ramazzotti E., Roderigo G., De Rosa V., et al. Effect of antibody to HIV-1 Tat protein on viral replication in vitro and progression of HIV-1 disease in vivo. J. AIDS Hum. Retrovirol. 10:1995;408-416
30. Cafaro A., Caputo A., Fracasso C., Maggiorella M.T., Goletti D., Baroncelli S., et al. Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 5:1999;643-650
31. Cafaro A., Titti F., Fracasso C., Maggiorella M.T., Baroncelli S., Caputo A., et al. Vaccination with DNA containing Tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P). Vaccine. 19:2001;2862-2877
32. Pauza C.D., Trivedi P., Wallace M., Ruckwardt T.J., Le Buanec H., Lu W., et al. Vaccination with Tat toxiod attenuates disease in simian/HIV-challenged macaques. Proc. Natl. Acad. Sci. U.S.A. 97:2000;3515-3519
33. Silvera P., Richardson M.W., Greenhouse J., Yalley-Ogunro J., Shaw N., Mirchandani J., et al. Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rheus macaques with human immunodeficiency virus Tat protein. J. Viol. 76:2002;3800-3809
34. Allen T.M., Mortara L., Liebl B.R., Jiang P., Calore B., Piekarczyk M., et al. Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication. J. Virol. 76:2002;4108-4112
35. Cui Z., Mumper R.J. Coating of cationized protein on engineered nanoparticles results in enhanced immune responses. Inter. J. Pharm. 238:2002;229-239
36. Cui Z., Mumper RJ. Genetic immunization using nanoparticles engineered from microemulsion precursors. Pharm. Res. 19:2002;939-946
37. Egan R., Yorkey C., Black R., Loh W., Stevens J., Woodward J. Peptide-specific T cell clonal expansion in vivo following immunization in the eye, an immune privileged site. J. Immunol. 157:1996;2262
38. Cui Z., Mumper R.J. Topical immunization using nanoengineered genetic vaccines. J. Control. Rel. 81:2002;173-184
39. DeAngelis R.L., Findlay J.W. Metabolism of synthetic surfactants. Clin. Perinatol. 20(4):1993;697-710
40. Schijns V. Immunological concepts of vaccine adjuvant activity. Curr. Opin. Immunol. 12:2000;456-463
41. + T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4. J. Immunol. 155:1995;1032
42. Parham P. The immune system. Taylor & Francis, London, 2000.
43. Kazzaz J., Neidleman J., Singh M., Ott G., O'Hagan D. Novel anionic microparticles are a potent adjuvant for the induction of cytotoxic T-lymphocytes against recombinant p55 gag from HIV-1. J. Control. Rel. 67:2000;347-356
44. Kovacsovics-Bankowski M., Clark K., Benacerraf B., Rock K.L. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. U.S.A. 90:1993;4942-4946
45. Kovacsovics-Bankowski M., Rock K.L. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science. 267:1995;243-246